Study shows one-fifth of prescribed cancer drugs initially denied coverage in Medicare were overturned when reviewed
Source ↗
👁 0
💬 0
A new study of cancer drugs denied by Medicare Part D insurance plans found that more than one-fifth of denials were overturned upon review by a contracted reviewer. This suggests there are a considerable number of inappropriate denials.
Youngmin Kwon, PhD
The study, led by Youngmin Kwon, PhD, a postdoctoral research fellow in the Department of Health Policy at Vanderbilt Health, implemented natural language processing to analyze the text of second-level appeals of cancer drugs denied unde
Youngmin Kwon, PhD
The study, led by Youngmin Kwon, PhD, a postdoctoral research fellow in the Department of Health Policy at Vanderbilt Health, implemented natural language processing to analyze the text of second-level appeals of cancer drugs denied unde
Comments (0)